Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cisbio Bioassays Launches Epigenetics Toolbox

Published: Thursday, September 27, 2012
Last Updated: Thursday, September 27, 2012
Bookmark and Share
Pioneer of HTRF® technology expands platform to address growing field of epigenetics therapeutic research.

Cisbio Bioassays has announced the launch of its epigenetics toolbox for use in drug discovery research.

Epigenetics is a crucial field of study for the pharmaceutical and biotechnology industries due to its large range of applications related to human health.

This epigenetics toolbox, which offers a robust and reliable resource for such studies and is based on HTRF® technology, was introduced in Europe at MipTec 2012 in Basel, Switzerland and will be released on October 1st in the United States at Discovery on Target 2012 in Boston, Massachusetts.

Cisbio Bioassays’ epigenetics toolbox is a selection of conjugates specifically developed by the company for epigenetics studies, in response to requests from pharmaceutical and biotechnology researchers for reagents that would help better understand how these events occur through epigenetic mechanisms and how they relate to multiple therapeutic areas and diseases such as metabolic, CNS and immune system disorders.

The toolbox works in combination with Cisbio Bioassays’ other HTRF-based reagents to provide a single, robust and easy-to-use technology for studying classes such as histone methylation and histone demethylation.

“Protein: protein interactions and modifications have long been front and center in drug discovery research and now epigenetics target classes have become highly sought after by researchers because of their broad span of applications,” said François Degorce, head of marketing and communications at Cisbio Bioassays.

Degorce continued, “Epigenetics has become one of Cisbio Bioassays’ core research programs in response to the high demand from clients for more specific study tools, like HTRF, that can be applied to this field. To meet this need, we will regularly implement new assays that allow for studying relevant enzymes and the way in which they function. In fact, our development of this first set of reagents parallels our global commitment to introducing novel tools to our growing catalogue, much as we have been doing with our kinase screening platform throughout the year.”

As part of the development of its kinase screening platform, Cisbio Bioassays has also launched two HTRF cellular kinase assays, Phospho-MEK1 and Phospho-MEK1/2.

These assays, designed for detecting and studying activated MEK when phosphorylated at Ser218 and 222 directly in whole cells, can be used for the investigation of the MAP kinase pathway and therefore the screening of potential anti-cancer therapeutic compounds.

Cisbio’s kinase screening platform now comprises 11 assays - Phospho-CREB (Ser133), Phospho-mTOR (Ser2448) and Phospho-EGFR were introduced in June 2012 - and additional kits are planned in the upcoming months.

All assays feature the benefits of HTRF technology: streamlined protocols, miniaturization and application to any phase of drug screening.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cisbio Bioassays and IGF Launch CNS Drug Discovery Research Program
Cisbio Bioassays, member of IBA Group and global provider of HTRF® (homogenous time resolved fluorescence) technology and services to facilitate drug discovery, has announced the launch of the GluSense research and development program in partnership with the Functional Genomics Institute of Montpellier, France.
Tuesday, November 30, 2010
Cisbio Bioassays Partners with Promega to Launch HaloTag® for Tag-lite®
Combination of HaloTag® and HTRF® technologies provides a new, flexible tool for cell surface receptor heterodimerization.
Thursday, September 23, 2010
Cisbio Bioassays Marks Second Milestone in China with new Demo Lab
Lab to support drug discovery customers in Asia by providing local training and services.
Thursday, July 22, 2010
Cisbio Bioassays Strengthens Presence in Asia
Global developer of drug screening tools and technologies now has local sales teams in China and South Korea.
Friday, November 06, 2009
Cisbio Bioassays Selects CyBio Robotic Workstation
The robotic workstation complements Cisbio’s expertise in creating and optimizing HTRF assays.
Wednesday, February 04, 2009
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!